FR21C1043I1 - - Google Patents

Info

Publication number
FR21C1043I1
FR21C1043I1 FR21C1043C FR21C1043I1 FR 21C1043 I1 FR21C1043 I1 FR 21C1043I1 FR 21C1043 C FR21C1043 C FR 21C1043C FR 21C1043 I1 FR21C1043 I1 FR 21C1043I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR21C1043I1 publication Critical patent/FR21C1043I1/fr
Application granted granted Critical
Publication of FR21C1043I2 publication Critical patent/FR21C1043I2/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR21C1043C 2012-05-22 2021-09-20 COMPOSITIONS COMPRISING SHORT-ACTING BENZODIAZEPINES Active FR21C1043I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168968 2012-05-22
EP13730128.9A EP2852389B1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines
PCT/EP2013/060543 WO2013174883A1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines

Publications (2)

Publication Number Publication Date
FR21C1043I1 true FR21C1043I1 (en) 2021-11-19
FR21C1043I2 FR21C1043I2 (en) 2022-10-07

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1043C Active FR21C1043I2 (en) 2012-05-22 2021-09-20 COMPOSITIONS COMPRISING SHORT-ACTING BENZODIAZEPINES

Country Status (42)

Country Link
US (2) US20150148338A1 (en)
EP (1) EP2852389B1 (en)
JP (1) JP6313286B2 (en)
KR (1) KR102116737B1 (en)
CN (2) CN108578413A (en)
AP (1) AP2014008084A0 (en)
AR (1) AR092008A1 (en)
AU (1) AU2013265295B2 (en)
BR (1) BR112014029108B1 (en)
CA (1) CA2874247C (en)
CL (1) CL2014003171A1 (en)
CO (1) CO7151503A2 (en)
DK (1) DK2852389T3 (en)
EA (1) EA032119B1 (en)
EC (1) ECSP14032553A (en)
ES (1) ES2651389T3 (en)
FR (1) FR21C1043I2 (en)
GE (1) GEP20186852B (en)
HK (1) HK1208164A1 (en)
HR (1) HRP20171872T1 (en)
HU (2) HUE037734T2 (en)
IL (1) IL235789B (en)
LT (2) LT2852389T (en)
LU (1) LUC00230I2 (en)
MA (1) MA37581B1 (en)
MX (1) MX368854B (en)
MY (1) MY185117A (en)
NL (1) NL301130I2 (en)
NO (2) NO2852389T3 (en)
NZ (1) NZ702063A (en)
PE (1) PE20150683A1 (en)
PH (1) PH12014502608A1 (en)
PL (1) PL2852389T4 (en)
PT (1) PT2852389T (en)
RS (1) RS56660B1 (en)
SG (1) SG11201407710VA (en)
SI (1) SI2852389T1 (en)
TN (1) TN2014000479A1 (en)
TW (1) TWI590826B (en)
UA (1) UA115063C2 (en)
WO (1) WO2013174883A1 (en)
ZA (1) ZA201408412B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007009128D1 (en) 2006-07-10 2010-10-21 Paion Uk Ltd BENZODIAZEPINE SALTS WITH SHORT-TERM EFFECT AND POLYMORPHIC FORMS THEREOF
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (en) 2013-03-04 2015-09-09 Ono Pharmaceutical Co EXCELLENT OXIDATION REACTION IN THE CONVERSION INDEX
WO2015076340A1 (en) * 2013-11-21 2015-05-28 小野薬品工業株式会社 Injectable composition for general anesthesia and/or sedation
PL3106004T3 (en) 2014-02-10 2024-02-19 Biolumic Limited Improvements in and relating to controlling characteristics of photosynthetic organisms
EP3116296B1 (en) 2014-03-14 2020-05-06 Biolumic Limited Method to improve crop yield and/or stress resistance
HUE047450T2 (en) * 2014-07-23 2020-04-28 Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd New benzodiazepine derivative and use thereof
CN107105625A (en) 2014-09-17 2017-08-29 拜欧卢米克有限公司 The method and products therefrom of seed treatment
CN105726495B (en) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 A kind of short-acting benzodiazepine salt pharmaceutical composition of injection and preparation method thereof
CN107198691A (en) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 A kind of pharmaceutical composition of auspicious horse azoles logical sequence
CN109641000A (en) * 2016-04-14 2019-04-16 Paion英国有限公司 The benzodiazepine * class of oral sucking and intranasal
WO2017198224A1 (en) * 2016-05-20 2017-11-23 江苏恒瑞医药股份有限公司 Pharmaceutical composition of remimazolam
CN109890198A (en) 2016-08-22 2019-06-14 拜欧卢米克有限公司 Seed treatment systems, devices and methods
CN108503644B (en) 2016-12-09 2019-06-14 成都倍特药业有限公司 A kind of hydrobromate and its preparation method and application of benzodiazepine * derivative
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (en) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 New solid form of compound hydrobromide, preparation method and application thereof
ES2803099B2 (en) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedure for obtaining amorphous remimazolam besilate
CN114478535B (en) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 Preparation method of crystal form Malun II of benzenesulfonic acid
CN112462015B (en) * 2020-11-18 2022-07-12 海南倍特药业有限公司 Method for detecting bacterial endotoxin of remazolam hydrobromide
CN114624351B (en) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 Analysis method of (R) - (-) -1-amino-2-propanol residues in pomazolam besylate bulk drug
WO2024126745A1 (en) * 2022-12-16 2024-06-20 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
PT801651E (en) 1995-01-06 2001-12-28 Hoffmann La Roche HYDROXIMETHYL-IMIDAZODIAZEPINS AND ITS ESTERS
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (en) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd Freeze-dried preparation
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
DE602007009128D1 (en) * 2006-07-10 2010-10-21 Paion Uk Ltd BENZODIAZEPINE SALTS WITH SHORT-TERM EFFECT AND POLYMORPHIC FORMS THEREOF
CN101352422B (en) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 Tetrodotoxin lyophilized powder formulation for injection and preparation method thereof
ES2564318T3 (en) * 2009-11-05 2016-03-21 Glaxosmithkline Llc Benzodiazepine Bromodomain Inhibitor
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (en) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 Tosilate of benzodiazepine derivative, its crystal forms, their preparation method and application

Also Published As

Publication number Publication date
CN104968348B (en) 2018-04-17
CA2874247C (en) 2020-07-28
MX2014014225A (en) 2015-06-17
MY185117A (en) 2021-04-30
TWI590826B (en) 2017-07-11
IL235789A0 (en) 2015-01-29
LTPA2021521I1 (en) 2021-10-11
JP2015517552A (en) 2015-06-22
BR112014029108A2 (en) 2017-06-27
LT2852389T (en) 2017-12-27
SG11201407710VA (en) 2015-01-29
MA20150233A1 (en) 2015-07-31
GEP20186852B (en) 2018-05-25
PH12014502608B1 (en) 2015-01-21
AP2014008084A0 (en) 2014-11-30
NL301130I2 (en) 2021-10-25
TW201400119A (en) 2014-01-01
LUC00230I2 (en) 2022-10-07
BR112014029108B1 (en) 2022-02-08
AR092008A1 (en) 2015-03-18
RS56660B1 (en) 2018-03-30
PL2852389T4 (en) 2022-02-21
CA2874247A1 (en) 2013-11-28
HK1208164A1 (en) 2016-02-26
EA201492160A1 (en) 2015-10-30
NO2021041I1 (en) 2021-09-20
CN108578413A (en) 2018-09-28
US20220040198A1 (en) 2022-02-10
IL235789B (en) 2019-07-31
NZ702063A (en) 2016-11-25
EP2852389B1 (en) 2017-10-18
ZA201408412B (en) 2016-09-28
NL301130I1 (en) 2021-09-22
PL2852389T3 (en) 2018-02-28
PH12014502608A1 (en) 2015-01-21
DK2852389T3 (en) 2017-12-18
HUS2100040I1 (en) 2021-10-28
EA032119B1 (en) 2019-04-30
TN2014000479A1 (en) 2016-03-30
MA37581B1 (en) 2016-07-29
SI2852389T1 (en) 2018-02-28
ES2651389T3 (en) 2018-01-26
FR21C1043I2 (en) 2022-10-07
ECSP14032553A (en) 2018-11-30
WO2013174883A1 (en) 2013-11-28
PE20150683A1 (en) 2015-06-03
AU2013265295B2 (en) 2017-08-31
AU2013265295A1 (en) 2015-01-22
MX368854B (en) 2019-10-18
CO7151503A2 (en) 2014-12-29
HRP20171872T1 (en) 2018-02-23
PT2852389T (en) 2017-12-13
CN104968348A (en) 2015-10-07
HUE037734T2 (en) 2018-09-28
JP6313286B2 (en) 2018-04-18
US20150148338A1 (en) 2015-05-28
UA115063C2 (en) 2017-09-11
KR102116737B1 (en) 2020-05-29
EP2852389A1 (en) 2015-04-01
NO2852389T3 (en) 2018-03-17
KR20150009601A (en) 2015-01-26
CL2014003171A1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
NL301130I1 (en)
BR112014017635A2 (en)
BR112014017614A2 (en)
BR112014019796A2 (en)
BR112014017625A2 (en)
BR112014017592A2 (en)
BR112014017646A2 (en)
BR112014017638A2 (en)
BR112014017634A2 (en)
BR112014017609A2 (en)
BR112014020183A2 (en)
BR112014017644A2 (en)
BR112014017647A2 (en)
BR112014017618A2 (en)
BR112014017630A2 (en)
BR112014017621A2 (en)
BR112014017622A2 (en)
BR112014017627A2 (en)
BR112014017623A2 (en)
BR112014017631A2 (en)
BR112014017641A2 (en)
BR112014020981A2 (en)
BR112014017636A2 (en)
BR112014017600A2 (en)
BR112014017596A2 (en)